Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

NCT01170650 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

441

Enrollment

INDUSTRY

Sponsor class

Stopped DSMB decision

Conditions

Ovarian Cancer

Interventions

DRUG: EC145
DRUG: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
DRUG: placebo
DRUG: EC20

Sponsor

Endocyte